Journal ArticleOPEN ACCESS

Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study

  • Sakai H
  • Veillon R
  • Cortot A
  • et al.
Annals of Oncology (2019) 30 vi108-vi109
DOI: 10.1093/annonc/mdz338.079
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

… recurrence. Among these patients, 190 patients were treated with gefitinib/erlotinib, 51 with afatinib and 55 with osimertinib … respectively. Four adenocarcinomas treated with gefitinib/erlotinib all harbored TP53 mutations at baseline …

Cite

CITATION STYLE

APA

Sakai, H., Veillon, R., Cortot, A. B., Felip, E., Mazieres, J., Morise, M., … Paik, P. K. (2019). Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study. Annals of Oncology, 30, vi108–vi109. https://doi.org/10.1093/annonc/mdz338.079

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free